Comparative Pharmacology
Head-to-head clinical analysis: ARESTIN versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTIN versus DECLOMYCIN.
ARESTIN vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic